TY - JOUR
T1 - Bicalutamide ('Casodex') 150mg in addition to standard care in patients with nonmetastatic prostate cancer
T2 - Updated results from a randomised double-blind phase III study (median follow-up 5.1y) in the early prostate cancer programme
AU - Wirth, M.
AU - Tyrrell, C.
AU - Delaere, K.
AU - Sánchez-Chapado, M.
AU - Ramon, J.
AU - Wallace, D. M.A.
AU - Hetherington, J.
AU - Pina, F.
AU - Heyns, C.
AU - Borchers, T.
AU - Morris, T.
AU - Armstrong, J.
N1 - Funding Information:
Editorial support was provided by Sarah Goodger, PhD; AstraZeneca provided financial assistance for this support.
PY - 2005/6
Y1 - 2005/6
N2 - Trial 24 is one of three placebo-controlled trials within the ongoing bicalutamide ('Casodex'+) Early Prostate Cancer (EPC) programme evaluating bicalutamide 150mg/day in addition to radical prostatectomy, radiotherapy or watchful waiting for T1b -4, any N, M0 prostate cancer. In Trial 24, at 5.1y median follow-up, the addition of bicalutamide significantly (P<0.0001) improved objective progression-free survival (PFS) and prostate-specific antigen PFS compared with standard care alone. There was no significant difference in overall survival (P = 0.746). In the context of the whole EPC programme, long-term bicalutamide is not appropriate for localised disease, yet provides advantages in delaying disease progression in patients with locally advanced prostate cancer.
AB - Trial 24 is one of three placebo-controlled trials within the ongoing bicalutamide ('Casodex'+) Early Prostate Cancer (EPC) programme evaluating bicalutamide 150mg/day in addition to radical prostatectomy, radiotherapy or watchful waiting for T1b -4, any N, M0 prostate cancer. In Trial 24, at 5.1y median follow-up, the addition of bicalutamide significantly (P<0.0001) improved objective progression-free survival (PFS) and prostate-specific antigen PFS compared with standard care alone. There was no significant difference in overall survival (P = 0.746). In the context of the whole EPC programme, long-term bicalutamide is not appropriate for localised disease, yet provides advantages in delaying disease progression in patients with locally advanced prostate cancer.
KW - Bicalutamide
KW - Clinical trial
KW - Nonsteroidal antiandrogen
KW - Prostatic neoplasms
UR - http://www.scopus.com/inward/record.url?scp=23944447196&partnerID=8YFLogxK
U2 - 10.1038/sj.pcan.4500799
DO - 10.1038/sj.pcan.4500799
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 15931272
AN - SCOPUS:23944447196
SN - 1365-7852
VL - 8
SP - 194
EP - 200
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
IS - 2
ER -